The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China

Por Xu, Jianlin, Ding, Guozheng, Zhang, Xueyan, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Wang, Huiming, Wu, Dan, Han, Baohui
Publicado no Onco Targets Ther (2016)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations

Por Xu, Jianlin, Zhang, Xueyan, Yang, Haitang, Ding, Guozheng, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Wang, Huimin, Han, Baohui
Publicado no Oncotarget (2016)